OBJECTIVES: To determine the Cost-Effectiveness analysis of novel agents in the first-line treatment options in transplant Ineligible Newly Diagnosed Multiple Myeloma patients from a partitioned survival model approach by 10-year therapeutic scheme option.

METHODS: In this study, we developed a partitioned survival model as innovative way to get a cost-effective analysis of the novel agents in the first-line treatment framework. In this study, three regimens were included: CyborD, VRD and as a comparator regimen DRd. All direct disease costs were estimated using SISMED, and Capitation Sufficiency Database. The QALYs were estimated using the utilities found in the Center for the evaluation of Value and Risk in Health (CEVR).

RESULTS: The use of DRd as first-line therapy for transplant ineligible patients in Colombia with multiple myeloma was expected to result in an additional 7.13 life years gained (LYG) vs 5.73 LYG for VRd, and the incremental cost per QALY gained with DRd vs VRD was $17.320.362 COP. The incremental cost was primarily attributable to the QALYs estimated during the use of monoclonal antibodies, cost of the management of AEs and the total costs of each treatment regimen.

CONCLUSIONS: Based on this study, the 10 years scenario the regimen treatment that include the economic evaluation performed in this study Daratumumab as first line-therapy are cost-effective in the Colombian health system perspective (>PIB per capita); and from 3- and 5-years scenarios, this regimen could be cost- effective since the incremental cost per QALY gained are between 1-3 PIB per capita.